Related Experiment Video
Updated: Jun 5, 2026
07:32
Assessing Iron Deposition in the Brains of 5xFAD Mice by Perls'/DAB Staining
Published on: May 23, 2025
Ceruloplasmin/Transferrin ratio changes in Alzheimer's disease
Rosanna Squitti1, Carlo Salustri, Mariacristina Siotto
1Department of Neuroscience, AFaR-Fatebenefratelli Hospital, 00186 Rome, Italy.
International Journal of Alzheimer'S Disease
|January 15, 2011
Summary
Systemic iron metabolism alterations, including increased ceruloplasmin/transferrin ratios, are linked to Alzheimer's disease (AD). These changes correlate with disease severity and brain atrophy, suggesting a broader role for systemic iron in AD pathogenesis.
Area of Science:
- Neuroscience
- Biochemistry
- Gerontology
Background:
- The relationship between iron and Alzheimer's disease (AD) is primarily studied through local iron accumulation in the brain.
- Systemic iron metabolism has not been extensively investigated in the context of AD.
Purpose of the Study:
- To investigate systemic variations in iron metabolism markers in Alzheimer's disease patients.
- To explore the correlation between these systemic markers and AD severity and brain atrophy.
Main Methods:
- Serum levels of iron, ceruloplasmin, and transferrin were measured.
- Transferrin saturation and ceruloplasmin to transferrin ratio (Cp/Tf) were calculated.
- Correlations with peroxide levels, MMSE scores, and medial temporal lobe atrophy were analyzed.
Main Results:
- Alzheimer's disease patients showed increased Cp/Tf ratios and transferrin saturation.
- Cp/Tf ratios positively correlated with peroxide levels and negatively with serum iron.
- Elevated ceruloplasmin, peroxides, and Cp/Tf inversely correlated with Mini-Mental State Examination (MMSE) scores.
- Medial temporal lobe atrophy correlated positively with Cp/Tf and negatively with serum iron.
Conclusions:
- Systemic iron alterations are associated with Alzheimer's disease.
- Findings suggest that local brain iron accumulation in AD should be considered within the context of broader systemic iron dysregulation.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...